Rehydra+ review: a 6-month non-cancelable plan

Rehydra+ Wellness (rehydraplus.com) advertises GLP-1 memberships from $119 a month. We read its full catalog out of its own store data in August 2026 — 23 products, prices pulled from the API rather than the marketing copy — and the memberships are not monthly. Every one of them is a six-month contract the site itself describes as non-cancelable, on two separate surfaces. That single term reorganizes everything else on this page.

What $119 a month actually costs

The membership tiers are priced per month and sold in six-month blocks you cannot exit. Semaglutide runs $119, $169 and $229 a month by dose tier; tirzepatide runs $169, $289 and $419. Multiply each by six and you have the real commitment: $714, $1,014 and $1,374 for semaglutide, and $1,014, $1,734 and $2,514 for tirzepatide.¹

There is no month-to-month membership rung anywhere on the site. That matters more than the headline being high or low, because a monthly figure implies a monthly decision, and here there is exactly one decision and it costs at least $714. Any ranking publishing "Rehydra+ from $119/month" is publishing a price nobody can buy for one month. The sixth question on our five-minute provider checklist is simply "can you leave?" — for these memberships the published answer is no.

The one thing here you can cancel

Rehydra+ also sells one-time supply packs, and those are ordinary purchases with no term attached. The smallest unit is four weeks. Semaglutide runs $149, $179, $199, $269 and $289 for four weeks across its five doses; tirzepatide runs $219, $249, $319, $449, $629 and $649 across six.¹ Eight- and twelve-week packs cost proportionally less per week.

Read those next to the memberships and the pitch inverts. Four weeks of 0.25 mg semaglutide costs $149 as a one-time pack against $119 a month on a plan you cannot leave — thirty dollars a month for the right to stop. Unless you are certain you will be on this medication for six months at a dose you have already tolerated, the pack is the rational purchase, and the fact that the cheaper number is the one with the lock attached is the whole design.

The catalog has routes we would not buy

Beyond GLP-1, Rehydra+ sells BPC-157, a BPC-157 and TB-500 stack, KPV, MOTS-c, sermorelin, tesamorelin, GHK-Cu, two blends, NAD+ and lipo-plus. Several of those are offered as oral products — oral BPC-157, oral KPV and oral tesamorelin — and oral bioavailability for those peptides is not established. Buying a peptide in a form that may not survive digestion is buying a price, not a treatment. The same principle runs through our piece on oral GLP-1 pills: the route is not a detail, it is most of whether the molecule reaches you at all.

It also sells testosterone therapy — $399 for ten weeks — as an ordinary item in a shopping cart. Whatever your view of testosterone telehealth, a controlled substance sitting in a WooCommerce checkout beside a peptide blend is a category of retail we would want more clinical friction around, not less.

Who is behind it, and what could not be verified

Three clinicians are named: John H. Hamilton, MD as medical director, Angie Tuzson, NP, and Jared Folwell, MD. None publishes an NPI, so none could be checked against the federal registry the way The Edit's medical director could. The pharmacy is never named — the site refers only to "our pharmacy partner". The corporate entity is written as RealHealth Ventures PLLS doing business as Rehydra+ Wellness, at a San Antonio address; we record the spelling as published.

The site claims LegitScript certification in prose, but the badge is a self-hosted image file linking to a keyword search rather than to a certification record, and no seal identifier appears anywhere on the site. That means the claim could not be verified — not that it is false. We checked by probing seal images directly, because the certification lookup page returns a normal page even for domains that were never certified, so the badge link proves nothing on its own.

The site says it serves patients in 20 states and never names them. The only state list on the site is a checkout dropdown containing all 50, which is a form control rather than a coverage disclosure. Since prescribing rules differ by state, a desk serving 20 of them and naming none has left the most consequential eligibility question for you to discover at checkout.

Payment, financing and refunds

This is a cart, so you pay for the product at checkout, before a provider reviews you, and the refund policy does not clearly address what happens if you are not approved. There are no returns or refunds on prescription or compounded medication once shipped. Financing is offered through Cherry, with a 2.99 per cent processing fee on credit-card down payments disclosed on the payment-plan page and nowhere else. A buy-now-pay-later option layered over a non-cancelable six-month contract is a combination worth sitting with before you click.

The regulatory screen

The trading name and the legal entity both returned zero company-column matches in the FDA's live warning-letter index in August 2026, against a positive control that correctly returned a known February 2026 letter for an unrelated telehealth seller.² Nothing in the enforcement record counts against this desk. Its problems are contractual and disclosure problems, not regulatory ones, and it is worth being precise about the difference.

Where it lands

Rehydra+ is the hardest desk in this batch to recommend and the easiest to describe: the monthly price is not monthly, the pharmacy is not named, the states are not listed, the certification cannot be verified, and the shelf includes oral routes with no established bioavailability alongside testosterone in a cart. If you buy here, buy a one-time pack, and do not sign a membership because it is thirty dollars cheaper. If you want a desk you can leave at the end of any month, Trellis Vitality at $150 and Auren Rx at $199 both publish an explicit monthly rung, and the rest of our research covers what to check before you commit to anything.